论文部分内容阅读
目的:观察评价米非司酮在子宫瘢痕妊娠治疗中的临床效果。方法:选择于2010年4月-2012年9月在我院接受治疗的子宫瘢痕妊娠患者28例,将这些患者随机分成对照组各观察组各14例,对照组组通过给予甲氨蝶呤治疗,观察组则通过甲氨蝶呤联合米非司酮治疗,对两组患者的临床治疗总有效率、不良反应发生率进行对比。结果:观察组患者的临床治疗总有效率显著高于对照组,分别为85.7%(12/14)和64.3%(9/12),两组比较差异显著(P<0.05),具有统计学意义;同时结果显示观察组的不良反应发生率为7.14%(1/14),明显低于对照组的28.6%(4/14),两组比较差异显著(P<0.05),具有统计学意义。结论:米非司酮在子宫瘢痕妊娠治疗中疗效确切,较为安全可靠,具有临床推广应用价值。
Objective: To observe and evaluate the clinical effect of mifepristone in the treatment of uterine scar pregnancy. Methods: 28 cases of uterine scar pregnancy treated in our hospital from April 2010 to September 2012 were randomly divided into control group (14 cases) and methotrexate control group , The observation group was treated with methotrexate combined with mifepristone, the total effective rate of clinical treatment of two groups of patients, the incidence of adverse reactions were compared. Results: The total effective rate of clinical treatment in observation group was significantly higher than that in control group (85.7% (12/14) and 64.3% (9/12) respectively), with significant difference between the two groups (P <0.05) The incidence of adverse reactions in the observation group was 7.14% (1/14), which was significantly lower than that in the control group (28.6%, 4/14). There was significant difference between the two groups (P <0.05). Conclusion: Mifepristone is effective in the treatment of uterine scar pregnancy, it is safe and reliable, and it has clinical application value.